DK3074038T3 - Fremgangsmåde til behandling af diabetisk nephropati - Google Patents

Fremgangsmåde til behandling af diabetisk nephropati Download PDF

Info

Publication number
DK3074038T3
DK3074038T3 DK14865202.7T DK14865202T DK3074038T3 DK 3074038 T3 DK3074038 T3 DK 3074038T3 DK 14865202 T DK14865202 T DK 14865202T DK 3074038 T3 DK3074038 T3 DK 3074038T3
Authority
DK
Denmark
Prior art keywords
vegf
antibody
compound
mice
seq
Prior art date
Application number
DK14865202.7T
Other languages
English (en)
Inventor
Ulf Eriksson
Annelie Falkevall
Annika Mehlem
Original Assignee
Csl Ltd
B Creative Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904595A external-priority patent/AU2013904595A0/en
Application filed by Csl Ltd, B Creative Sweden Ab filed Critical Csl Ltd
Application granted granted Critical
Publication of DK3074038T3 publication Critical patent/DK3074038T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)

Claims (10)

1. Forbindelse der inhiberer VEGF-B-signalering til anvendelse i behandling af diabetisk nephropati hos et individ der lider af diabetisk nephropati, hvor forbindelsen der inhiberer VEGF-B-signalering er: (i) et protein omfattende en antistof-variabel region der binder til eller specifikt binder til VEGF-B og neutraliserer VEGF-B-signalering; eller (ii) en nukleinsyre der inhiberer eller forebygger ekspression af VEGF-B.
2. Forbindelse til anvendelse ifølge krav 1, hvor individet lider af diabetes og mikroalbuminuri eller makroalbuminuri.
3. Forbindelsen til anvendelse ifølge krav 1 eller 2, hvor forbindelsen administreres i en mængde der er effektiv til at tilvejebringe én eller flere af følgende virkninger: • nedsætte eller forebygge hypertension; • nedsætte eller forebygge glomerulær og/eller tubulær sclerose; • nedsætte eller forebygge mesangial ekstracellulær matriksdeponering og/eller unormal fortykkelse af den glomerulære basalmembran; • nedsætte eller forebygge glomerulær mesangial ekspansion; • nedsætte eller forebygge glomerulære vaskulære omlejninger; • nedsætte eller forebygge nyrelipidakkumulation; • nedsætte eller forebygge glomerulær lipidakkumulation; • nedsætte eller forebygge glomerulær kollagendeponeringer og/eller arteriolær hyaliose; og/eller • nedsætte eller forebygge makroalbuminuri.
4. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor forbindelsen er et protein omfattende Fv.
5. Forbindelsen til anvendelse ifølge krav 4, hvor et protein er valgt fra gruppen bestående af: (i) et enkeltkæde-Fv-fragment (scFv); (ii) et dimert scFv (di-scFv); eller (iii) et diabody; (iv) et triabody; (v) et tetrabody; (vi) et Fab; (vii) et F(ab')2; (viii) et Fv; (ix) én af (i) til (viii) bundet til en konstant region af et antistof, Fc eller en tung kæde konstant domæne (Ch) 2 og/eller Ch3; eller (x) et antistof.
6. Forbindelsen til anvendelse ifølge krav 1, hvor forbindelsen er et protein omfattende en antistof-variabel region der kompetitivt inhiberer bindingen af et antistof omfattende en tung kæde variabel region (Vh) omfattende et sekvenssæt vist i SEQ ID NO: 3 og en let kæde variabel region (Vl) omfattende et sekvenssæt vist i SEQ ID NO: 4 til VEGF-B.
7. Forbindelsen til anvendelse ifølge krav 6, hvor forbindelsen er et protein omfattende en humaniseret form af VH-regionen som vist i SEQ ID NO: 3 eller Vi_-regionen som vist i SEQ ID NO: 4 eller forbindelsen er en humaniseret form af et antistof omfattende VH-regionen som vist i SEQ ID NO: 3 og Vi_-regionen som vist i SEQ ID NO:4.
8. Forbindelsen til anvendelse ifølge krav 7, hvor forbindelsen er et antistof bestående af Vh omfattende et sekvenssæt som vist i SEQ ID NO: 5 og Vl omfattende et sekvenssæt som vist i SEQ ID NO: 6.
9. Forbindelsen til anvendelse ifølge kravene 1-3, hvor forbindelsen er en nukleinsyre valgt fra gruppen af antisense, siRNA, RNAi, ribozym og DNAzym.
10. Forbindelsen til anvendelse ifølge et hvilket som helst af kravene 1 til 9, der er formuleret til administration med en yderligere forbindelse, hvor den yderligere forbindelse behandler eller forebygger nephropati eller behandler, forebygger, eller forsinker progression af diabetes.
DK14865202.7T 2013-11-28 2014-11-28 Fremgangsmåde til behandling af diabetisk nephropati DK3074038T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013904595A AU2013904595A0 (en) 2013-11-28 Method of treating nephropathy
PCT/AU2014/050387 WO2015077845A1 (en) 2013-11-28 2014-11-28 Method of treating nephropathy

Publications (1)

Publication Number Publication Date
DK3074038T3 true DK3074038T3 (da) 2019-03-11

Family

ID=53198116

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14865202.7T DK3074038T3 (da) 2013-11-28 2014-11-28 Fremgangsmåde til behandling af diabetisk nephropati

Country Status (14)

Country Link
US (3) US9803008B2 (da)
EP (2) EP3530286A1 (da)
JP (2) JP6612246B2 (da)
KR (1) KR102339724B1 (da)
CN (1) CN105873608A (da)
AU (1) AU2014354588B2 (da)
BR (1) BR112016012248A2 (da)
CA (1) CA2931357C (da)
DK (1) DK3074038T3 (da)
ES (1) ES2711882T3 (da)
PL (1) PL3074038T3 (da)
RU (1) RU2718054C2 (da)
TR (1) TR201900665T4 (da)
WO (1) WO2015077845A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105873608A (zh) 2013-11-28 2016-08-17 杰特有限公司 治疗肾病的方法
EP3220952B1 (en) 2014-11-17 2021-04-21 CSL Limited Method of treating or preventing stroke
RU2651895C2 (ru) * 2015-12-01 2018-04-24 Алексей Николаевич Вачёв Способ прогнозирования клинического эффекта после операции реваскуляризации почек у больных с ишемической нефропатией
EP3445450A4 (en) * 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
RU2754509C1 (ru) * 2020-12-21 2021-09-02 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ лечения первичной мембранозной нефропатии с нефротическим синдромом и повышенным уровнем анти-plar2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0569141A3 (en) 1992-04-14 1994-10-26 Hybritech Inc Method for inhibiting the growth of multidrug-resistant tumors by antibodies.
JP3444885B2 (ja) 1992-08-21 2003-09-08 フリーイェ・ユニヴェルシテイト・ブリュッセル Ｌ鎖欠落免疫グロブリン
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DK1624060T3 (da) 1998-03-20 2012-04-10 Commw Scient Ind Res Org Kontrol af genekspression
EP3214177A3 (en) 1998-04-08 2017-11-22 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
US6219158B1 (en) 1998-07-31 2001-04-17 Hewlett-Packard Company Method and apparatus for a dynamically variable scanner, copier or facsimile secondary reflective surface
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
ZA200607588B (en) * 2004-02-11 2008-05-28 Fibrogen Inc CTGF as target for the therapy of diabetic nephropathy
CN101884789A (zh) * 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
US7977071B2 (en) 2004-06-02 2011-07-12 Adalta Pty Ltd. Binding moieties based on shark ignar domains
PL1781321T3 (pl) * 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009504685A (ja) 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド 新世界霊長類フレームワーク領域を用いる設計された抗体
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2010080238A2 (en) 2008-12-18 2010-07-15 3M Innovative Properties Company Telechelic hybrid aerogels
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
WO2013101954A1 (en) * 2011-12-28 2013-07-04 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
CN105873608A (zh) 2013-11-28 2016-08-17 杰特有限公司 治疗肾病的方法

Also Published As

Publication number Publication date
US20200010541A1 (en) 2020-01-09
CN105873608A (zh) 2016-08-17
US10407498B2 (en) 2019-09-10
WO2015077845A1 (en) 2015-06-04
TR201900665T4 (tr) 2019-02-21
US11261243B2 (en) 2022-03-01
JP6612246B2 (ja) 2019-11-27
KR20160083121A (ko) 2016-07-11
JP2016540047A (ja) 2016-12-22
JP6802342B2 (ja) 2020-12-16
EP3530286A1 (en) 2019-08-28
RU2718054C2 (ru) 2020-03-30
JP2020029459A (ja) 2020-02-27
RU2016125513A (ru) 2018-01-10
BR112016012248A2 (pt) 2017-10-17
US20170037119A1 (en) 2017-02-09
AU2014354588A1 (en) 2016-06-02
EP3074038A4 (en) 2017-08-02
EP3074038B1 (en) 2019-01-02
US20180086824A1 (en) 2018-03-29
ES2711882T3 (es) 2019-05-08
US9803008B2 (en) 2017-10-31
KR102339724B1 (ko) 2021-12-17
EP3074038A1 (en) 2016-10-05
CA2931357C (en) 2022-07-12
CA2931357A1 (en) 2015-06-04
AU2014354588B2 (en) 2020-07-02
PL3074038T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
US11261243B2 (en) Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody
US20240002488A1 (en) Method of treating or preventing liver conditions
KR102466794B1 (ko) 상처 치료 방법
JP7465210B2 (ja) 虚血－再灌流障害の治療又は予防方法
US20210269517A1 (en) Method of treating wasting disorders